PDCD1LG2 Antibody, FITC conjugated

Code CSB-PA017667EC01HU
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) PDCD1LG2 Polyclonal antibody
Uniprot No. Q9BQ51
Target Names PDCD1LG2
Alternative Names B7 dendritic cell molecule antibody; B7-DC antibody; B7DC antibody; bA574F11.2 antibody; Btdc antibody; Butyrophilin B7 DC antibody; Butyrophilin B7-DC antibody; Butyrophilin B7DC antibody; CD 273 antibody; CD273 antibody; CD273 antigen antibody; MGC142238 antibody; MGC142240 antibody; PD 1 ligand 2 antibody; PD L2 antibody; PD-1 ligand 2 antibody; PD-L2 antibody; PD1 ligand 2 antibody; PD1L2_HUMAN antibody; PDCD 1 ligand 2 antibody; PDCD1 ligand 2 antibody; PDCD1L2 antibody; Pdcd1lg2 antibody; PDL 2 antibody; PDL2 antibody; Programmed cell death 1 ligand 2 antibody; Programmed death ligand 2 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Programmed cell death 1 ligand 2 protein (20-220AA)
Immunogen Species Homo sapiens (Human)
Conjugate FITC
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production (By similarity).
Gene References into Functions
  1. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID: 29122656
  2. High PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative Non-small Cell Lung Cancer. PMID: 30275216
  3. The high-affinity PD-1 mutant could compete with the binding of antibodies specific to PD-L1 or PD-L2 on cancer cells. PMID: 29890018
  4. the binding affinities of the PD-1-PD-L1/PD-L2 co-inhibitory receptor system, was characterized. PMID: 27447090
  5. Tumor PDCD1LG2 expression is inversely associated with Crohn-like lymphoid reaction to colorectal cancer, suggesting a possible role of PDCD1LG2-expressing tumor cells in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis. PMID: 29038297
  6. The biopsy tumor key protein measurements demonstrate substantial between-tumor variation in expression ratios of these proteins and suggest that programmed cell death 1 ligand 2 PD-L2 is present in some tumors at levels sufficient to contribute to programmed cell death-1 PD-1-dependent T-cell regulation and possibly to affect responses to PD-1- and programmed cell death 1 ligand 1 PD-L1-blocking drugs. PMID: 28546465
  7. the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis. PMID: 28754154
  8. in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1 PMID: 27837027
  9. Clinical response to pembrolizumab in patients with head and neck squamous cell carcinoma (HNSCC)may be related partly to blockade of PD-1/PD-L2 interactions. Therapy targeting both PD-1 ligands may provide clinical benefit in these patients. PMID: 28619999
  10. PD-L2 is regulated by both interferon beta and gamma signaling. PMID: 28494868
  11. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma PMID: 27456947
  12. Data suggest that hormonal 1,25-dihydroxyvitamin D is a direct transcriptional inducer of genes encoding PDL1 and PDL2 in myeloid cells/macrophages; this up-regulation of gene expression appears to be species- and cells-specific. PMID: 29061851
  13. PD-L2 copy number gains were not related to PD-L2 augmentation in non-small cell lung cancer. PMID: 27050074
  14. PD-L2 expression has been reported in 52% of esophageal adenocarcinomas but little is known about the expression of other immune checkpoints PMID: 28561677
  15. Low PD-L2 expression is associated with pediatric solid tumors. PMID: 28488345
  16. this study shows that higher PD-L2 expression on blood dendritic cells, from Plasmodium falciparum-infected individuals, correlates with lower parasitemia PMID: 27533014
  17. PD-L1/PD-L2 copy number alterations are a defining feature of classical Hodgkin lymphoma. PMID: 27069084
  18. PDL2 was overexpressed in Epstein Barr virus-associated gastric adenocarcinoma. PMID: 26980034
  19. higher expression of PD-L1 and PD-L2 on CD1a(+) cells than that on CD83(+) cells in cutaneous squamous cell carcinoma tumour tissues may contribute to negative regulation in anti-tumour immune responses PMID: 28052400
  20. stable ectopic expression of wild-type PDCD1LG2 and the PDCD1LG2-IGHV7-81 fusion showed, in coculture, significantly reduced T-cell activation. PMID: 27268263
  21. The expression levels of PD-1, PD-L1 and PD-L2 in CD3(+) T cells and CD19(+) B cells and serum IFN-gamma level in progressive hepatocellular carcinoma patients were significantly higher than controls. PMID: 27609582
  22. Downregulation of the immunosuppressive molecules, PD-1 and PD-L1, may imply that over-activation of immune cells in multiple sclerosis occurs through signaling dysfunction of these molecules and PD-L2 plays no important role in this context PMID: 27921410
  23. an IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma PMID: 27564404
  24. High PD-L2 expression is associated with Renal Cell Carcinoma. PMID: 26464193
  25. knocking down in dendritic cells results in activation of inflammatory T cells PMID: 26599163
  26. We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 cervical and 10 of 23 vulvar squamous cell carcinomas PMID: 26913631
  27. PD-L2 expression was neither associated with VEGF-TKI responsiveness nor patients' outcome PMID: 26424759
  28. PD-L1 and PD-L2 are useful new markers for identifying select histiocyte and dendritic cell disorders and reveal novel patient populations as rational candidates for immunotherapy PMID: 26752545
  29. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. PMID: 26317899
  30. the inflammatory environment in Barrett's esophagus and esophageal adenocarcinoma may contribute to the expression of PD-L2. PMID: 26081225
  31. PDL2 could promote the ability of human placenta-derived mesenchymal stromal cells to augment the secretion of IL-10. PMID: 26432559
  32. We suggest that decreased expression of programmed death-ligand 1, 2 on psoriatic epidermis can contribute to its chronic unregulated inflammatory characteristics. PMID: 26133691
  33. Suggest role for PD-L2 in recurrence of hepatitis C infection post orthotopic liver transplantation. PMID: 25675203
  34. Report PD-L2 expression in breast neoplasms. PMID: 26541326
  35. Data indicate that pulmonary pleomorphic carcinoma (PC) very frequently express CD274 antigen (PD-L1) and CD273 antigen (PD-L2). PMID: 26329973
  36. PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma is associated with an increased number of CD8(+) tumor infiltrating lymphocytess and increased MET expression. PMID: 25662388
  37. Results show that human-derived chordoma cell lines demonstrate inducible expression of PD-L1 and PD-L2, and that primary chordoma tissue shows variable expression of PD-1 and PD-L1 in infiltrating immune cells PMID: 25349132
  38. conclude that PD-L2 protein is robustly expressed by the majority of primary mediastinal (thymic) large B-cell lymphomas PMID: 25025450
  39. PD-1/PD-Ls pathways on PMCs inhibited proliferation and adhesion activity of CD4+ T cells, suggesting that Mycobacterium tuberculosis might exploit PD-1/PD-Ls pathways to evade host cell immune response in human. PMID: 24406080
  40. High Expression of PD-L2 is associated with myelodysplastic syndromes. PMID: 24270737
  41. Data indicate that the bone morphogenetic proteins (BMPs) signaling pathway regulates PD-L1 and PD-L2 expression in monocyte-derived dendritic cells (MoDCs) during the maturation process. PMID: 24532425
  42. Recurrent genomic rearrangement events in CD274 and PDCD1LG2 underlie an immune privilege phenotype in a subset of B-cell lymphomas. PMID: 24497532
  43. PD-L1 and PD-L2 expressed on hPMSCs could inhibit the hPMSCs-mediated up-regulation on the expression of IL-17 secreted by peripheral blood T cells PMID: 23388330
  44. Macrophages from infected animals show increased expression of PDL2 and CD80 that was dependent from the sex of the host. PMID: 23533995
  45. expression of PD-1 and its ligands, PD-L1 and PD-L2, in liver biopsies from HBV-related acute-on-chronic liver failure (HBV-ACLF) and chronic hepatitis B (CHB) patients were analyzed; results showed all 3 molecules were observed in the HBV-ACLF samples and levels were significantly higher than in CHB PMID: 22895698
  46. Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID: 22322668
  47. Data suggest that brain endothelial cells contribute to control T cell transmigration into the CNS and immune responses via PD-L2 but not PD-L1 expression. PMID: 22067141
  48. increased expression of PD-L2, as a costimulatory molecule, may have an important modulatory function on the local immune responses of OLP in vivo. PMID: 21457347
  49. Data suggest that PD-L1 may contribute to negative regulation of the immune response in chronic hepatitis B, and that PD-1 and PD-L1 and 2 may play a role in immune evasion of tumors. PMID: 21876620
  50. Our results suggest that PD-1 G-536A, PD-L1 A8923C and PD-L2 C47103T polymorphisms are associated with the presence of ankylosing spondylitis. PMID: 21791547

Show More

Hide All

Subcellular Location Isoform 3: Secreted, SUBCELLULAR LOCATION: Isoform 2: Endomembrane system, Single-pass type I membrane protein, SUBCELLULAR LOCATION: Isoform 1: Cell membrane, Single-pass type I membrane protein
Protein Families Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity Highly expressed in heart, placenta, pancreas, lung and liver and weakly expressed in spleen, lymph nodes and thymus.
Database Links

HGNC: 18731

OMIM: 605723

KEGG: hsa:80380

STRING: 9606.ENSP00000380855

UniGene: Hs.532279


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1